Lamond David
SEC insider (Form 3/4/5 filer). CIK 0001770790. Director at Quince Therapeutics, Inc. (QNCX). 4 reported Form 4/5 transactions since Sep 2024; latest on Jun 11, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Lamond David has filed insider reports for
- Quince Therapeutics, Inc. (QNCX): Director
Lamond David
CIK: 0001770790
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Quince Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 11, 2026QNCX
Quince Therapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
2.7K shares- - Jan 2, 2026QNCX
Quince Therapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
29.4K shares- - Jun 4, 2025QNCX
Quince Therapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
27K shares- - Jan 2, 2025QNCX
Quince Therapeutics, Inc.
AwardDirectDirector Stock Option (right to buy)
47.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 11, 2026 | QNCX Quince Therapeutics, Inc. | Award Director Stock Option (Right to Buy) | 2,700 | - | - | Direct |
| Jan 2, 2026 | QNCX Quince Therapeutics, Inc. | Award Director Stock Option (Right to Buy) | 29,423 | - | - | Direct |
| Jun 4, 2025 | QNCX Quince Therapeutics, Inc. | Award Director Stock Option (Right to Buy) | 27,000 | - | - | Direct |
| Jan 2, 2025 | QNCX Quince Therapeutics, Inc. | Award Director Stock Option (right to buy) | 47,587 | - | - | Direct |
1-4 of 4 transactions